APA

Shah P. I., Bush A., Canny G. J., Colin A. A., Fuchs H. J., Geddes D. M., Johnson C. A., Light M. C., Scott S. F. & Tullis D. E. (19951127). Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. : The European respiratory journal.

Chicago

Shah P I, Bush A, Canny G J, Colin A A, Fuchs H J, Geddes D M, Johnson C A, Light M C, Scott S F and Tullis D E. 19951127. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. : The European respiratory journal.

Harvard

Shah P. I., Bush A., Canny G. J., Colin A. A., Fuchs H. J., Geddes D. M., Johnson C. A., Light M. C., Scott S. F. and Tullis D. E. (19951127). Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. : The European respiratory journal.

MLA

Shah P I, Bush A, Canny G J, Colin A A, Fuchs H J, Geddes D M, Johnson C A, Light M C, Scott S F and Tullis D E. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. : The European respiratory journal. 19951127.